Effects of combined use of Alpelisib and Fulvestrant

The combination of Alpelisib (Alpelisib) - Piqray and Fulvestrant is currently recognized internationally as one of the highly effective combinations for PIK3CA mutant HR-positive, HER2-negative breast cancer . Apelvist blocks the metabolism and survival signals required for cancer cell growth by inhibiting the PI3Kα signaling pathway, while fulvestrant weakens the estrogen-dependent growth mechanism of tumor cells by selectively degrading the estrogen receptor (ER). The synergistic effect of the two is equivalent to applying pressure from the two key dimensions of "signaling pathway" and "hormone dependence" at the same time, preventing cancer cells from continuing to proliferate, thereby effectively delaying the disease.

Practice has shown that this combination is especially suitable for patients who have developed resistance after receiving aromatase inhibitors (such as letrozole, anastrozole, etc.). Researchers found that when endocrine therapy alone cannot continue to control tumors, PIK3CA mutations become the main driving mechanism of drug resistance, and apelvis precisely targets this molecular target, allowing fulvestrant to regain its inhibitory effect. This "reversal of drug resistance" property is the core value of the combination of apelvis + fulvestrant.

In clinical application, this combination regimen usually consists of daily oral administration of apelvis combined with fulvestrant injection. Most patients show signs of stable disease or tumor shrinkage within a few months after treatment. In addition to improving progression-free survival, the patient's overall quality of life is also improved because this regimen is less toxic than chemotherapy and can be taken orally, making it suitable for long-term maintenance treatment.

Of course, doctors still need to pay attention to some metabolic adverse reactions when using combination regimens, such as hyperglycemia, rash or diarrhea, etc. These can usually be controlled by adjusting the dosage or auxiliary drugs. With the popularization of molecular detection technology, more and more breast cancer patients will be able to benefit from this precision treatment through PIK3CA mutation detection in the future.

Reference materials:https://www.piqray.com/